AI Article Synopsis
- Oral alendronic acid was studied for its potential effects on Modic changes (MCs) and low back pain (LBP) in adults, compared to a control group not receiving any anti-osteoporotic medication.
- The study involved 82 subjects, with 41 receiving the medication for at least a year, and MRI results showed a significantly lower prevalence and severity of MCs in the treatment group.
- Findings suggest that oral alendronic acid may help reduce MC-related low back pain in individuals also suffering from osteoporosis.
Article Abstract
Background: Low back pain (LBP) affects a significant proportion of the adult population. Potent anti-resorptive drugs such as intravenous zoledronic acid have been demonstrated to reduce Modic changes (MCs) upon magnetic resonance imaging (MRI) of the spine and concomitantly decrease associated LBP. It is uncertain whether oral alendronic acid has a similar effect.
Methods: 82 subjects were recruited in this case-control study. Treatment subjects (n = 41) received oral alendronic acid treatment for at least 1-year and were matched by gender and age (± 2) to control subjects (n = 41) not receiving any anti-osteoporotic medication. The prevalence, type, and extent of MCs were quantified upon T1 and T2-weighted MRIs of the lumbosacral spine.
Results: Treatment subjects received oral alendronic acid for 124.0 ± 62.1 weeks at the time of MRI assessment and exhibited a lower prevalence of MCs over the lumbosacral spine (18/41 vs. 30/41, p < 0.001) as compared to control subjects. Amongst both groups, type 2 MCs were predominant. Quantification of type 2 MCs in treatment subjects revealed a significant reduction in area (113 ± 106 mm vs. 231 ± 144 mm, p < 0.01) and volume (453 ± 427 mm vs. 925 ± 575 mm, p < 0.01) affected by type 2 MCs in comparison to matched controls.
Conclusion: Oral alendronic acid may be useful in the treatment of MC-associated LBP in patients with concomitant osteoporosis.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11089688 | PMC |
| http://dx.doi.org/10.1186/s13018-024-04780-2 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
An Aptamer Sensor Based on Alendronic Acid-Modified Upconversion Nanoparticles Combined with Magnetic Separation for Rapid and Sensitive Detection of Thiamethoxam.
Foods
January 2025
College of Food Science and Technology, Nanjing Agricultural University, Nanjing 210095, China.
The widespread use of thiamethoxam has led to pesticide residues that have sparked global concerns regarding ecological and human health risks. A pressing requirement exists for a detection method that is both swift and sensitive. Herein, we introduced an innovative fluorescence biosensor constructed from alendronic acid (ADA)-modified upconversion nanoparticles (UCNPs) linked with magnetic nanoparticles (MNPs) via aptamer recognition for the detection of thiamethoxam.
View Article and Find Full Text PDFEvaluation and analysis of efficacy in bisphosphonate treatment of chronic nonbacterial osteomyelitis.
Hua Xi Kou Qiang Yi Xue Za Zhi
February 2025
State Key Laboratory of Oral Diseases & National Center for Stomatology & National Clinical Research Center for Oral Diseases & Dept. of Pharmacy, West China Hospital of Stomatology, Sichuan University, Chengdu 610041, China.
Objectives: This study aimed to analyze the influence of drug factors on the efficacy of bisphosphonate for chronic nonbacterial osteomyelitis to provide a reference for clinical treatment and promote clinical rational drug use by evaluation of effectiveness and safety of bisphosphonate treatment of chronic nonbacterial osteomyelitis.
Methods: Literature on the treatment of chronic nonbacterial osteomyelitis by using bisphosphonate was collected and analyzed from PubMed, Medline, Embase, Cochrane, ISI Web of Knowledge, CNKI, VIP, and Wanfang databases.
Results: A total of 489 cases were collected, with an average complete response rate of clinical presentation, laboratory tests and imaging findings of 80.
Preparation and preclinical evaluation of Ga-labeled alendronate analogs for diagnosis of bone metastases.
Dalton Trans
January 2025
Key Laboratory for Experimental Teratology of the Ministry of Education and Center for Experimental Nuclear Medicine, School of Basic Medical Sciences, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, 250012, China.
Bone is one of the most common target organs for distant metastases of solid tumors, which imposes a heavy burden on society. Early diagnosis of bone metastases is of great significance and positron emission tomography (PET) imaging plays an important role in the diagnosis of bone metastases. PET tracers applied for diagnosing bone metastases are constantly being updated, but they all have certain limitations like a relatively low bone/kidney ratio or no capacity to label therapeutic radionuclides.
View Article and Find Full Text PDFDesign and evaluation of a multi-responsive dual-modality bone-targeted drug delivery vehicle for the treatment of osteosarcoma.
Int J Pharm
January 2025
Key Laboratory of Modern Preparation of TCM, Ministry of Education, Jiangxi University of Chinese Medicine, Nanchang 330004 China; School of Pharmaceutics, China Pharmaceutical University, 639 Longmian Avenue, Nanjing 211198 China. Electronic address:
The combination of chemotherapy and photothermal therapy not only improves the therapeutic effect but also limits the side effects of drugs. Herein, a multi-responsive dual-modality bone-targeted drug delivery vehicle for the treatment of osteosarcoma was designed by utilizing alendronate sodium as a bone-targeting ligand for the targeted delivery of doxorubicin (DOX) loaded polydopamine nanoparticles (PDA NPs) coated with γ-polyglutamic acid (APC@PDA/DOX NPs). The average size of spherical NPs was 140.
View Article and Find Full Text PDFDrug-Induced Pulmonary Fibrosis: National Database Analysis.
Biomedicines
November 2024
Pharmacovigilance Center, Information and Methodological Center for Expert Evaluation, Record and Analysis of Circulation of Medical Products Under the Federal Service for Surveillance in Healthcare, 4-1 Slavyanskaya Square, 109074 Moscow, Russia.
Background/objectives: Pulmonary fibrosis (PF) results in a progressive decline of lung function due to scarring. Drugs are among the most common causes of PF. The objective of our study was to reveal the structure of drugs involved in PF development.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!